Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N-acetylcysteine challenge in rhesus monkeys

Synapse

Volumn 67, Issue 8, 2013, Pages 489-501

  Sandiego, Christine M ^a,b   Nabulsi, Nabeel ^b   Lin, Shu Fei ^b   Labaree, David ^b   Najafzadeh, Soheila ^b   Huang, Yiyun ^b   Cosgrove, Kelly ^b,c   Carson, Richard E ^a,b  

^a Yale University   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allosteric modulator; MGluR5 radioligand; NAC; Nonhuman primate; PET; Test retest

Indexed keywords

ABP 688 C 11; ACETYLCYSTEINE; CARBON 11; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BABOON; CONTROLLED STUDY; FEMALE; GRAY MATTER; IMAGE PROCESSING; IMAGE RECONSTRUCTION; KINETICS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RECEPTOR BINDING; RHESUS MONKEY;

ACETYLCYSTEINE; ANIMALS; BRAIN; CARBON RADIOISOTOPES; FEMALE; MACACA MULATTA; MALE; OXIMES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; TISSUE DISTRIBUTION;

EID: 84879555992     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21656     Document Type: Article

References (43)

1. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, Auberson YP, Gasparini F, Schubiger PA. 2006. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 47:698-705.
2. Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. 2002. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 22:9134-9141.
3. Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I. 2008. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 33:1760-1772.
4. Carroll FI. 2008. Antagonists at metabotropic glutamate receptor subtype 5 structure activity relationships and therapeutic potential for addiction. Addict Rev 1141:221-232.
5. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P. 1993. Comparison of bolus and infusion methods for receptor quantitation-Application to [F-18] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42.
6. Chen HH, Stoker A, Markou A. 2010. The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology 209:343-350.
7. Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 2012. (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry 71:1022-1025.
8. Cleva RM, Olive MF. 2011. Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules 16:2097-2106.
9. Cleva RM, Gass JT, Widholm JJ, Olive MF. 2010. Glutamatergic targets for enhancing extinction learning in drug addiction. Curr Neuropharmacol 8:394-408.
10. Cosgrove KE, Galvan EJ, Barrionuevo G, Meriney SD. 2011. mGluRs modulate strength and timing of excitatory transmission in hippocampal area CA3. Mol Neurobiol 44:93-101.
11. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. 2010. Measuring drug occupancy in the absence of a reference region: The Lassen plot re-visited. J Cereb Blood Flow Metab 30:46-50.
12. de Bartolomeis A, Sarappa C, Magara S, Iasevoli F. 2012. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol 682:1-11.
13. Dean O, Giorlando F, Berk M. 2011. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 36:78-86.
14. Delforge J, Syrota A, Mazoyer BM. 1990. Identifiability analysis and parameter-identification of an in vivo ligand-receptor model from PET data. IEEE Trans Biomed Eng 37:653-661.
15. DeLorenzo C, Kumar JS, Mann JJ, Parsey RV. 2011a. In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J Cereb Blood Flow Metab 31:2169-2180.
16. DeLorenzo C, Milak MS, Brennan KG, Kumar JS, Mann JJ, Parsey RV. 2011b. In vivo positron emission tomography imaging with [(1)(1)C]ABP688: Binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging 38:1083-1094.
17. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, Burger C, Auberson YP, Sovago J, Stockmeier CA, Buck A, Hasler G. 2011. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 168:727-734.
18. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. 2008. N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility. Expert Opin Biol Ther 8:1955-1962.
19. Elmenhorst D, Minuzzi L, Aliaga A, Rowley J, Massarweh G, Diksic M, Bauer A, Rosa-Neto P. 2010. In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. J Cereb Blood Flow Metab 30:1538-1549.
20. Gunn RN, Gunn SR, Cunningham VJ. 2001. Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21:635-652.
21. Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M. 2012. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab 32:874-883.
22. Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, Cosford ND, Roppe J, Kamenecka T, Patel S, Gibson RE, Sanabria S, Riffel K, Eng W, King C, Yang X, Green MD, O'Malley SS, Hargreaves R, Burns HD. 2005. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse 56:205-216.
23. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. 2000. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27:627-630.
24. Hintermann S, Vranesic I, Allgeier H, Brulisauer A, Hoyer D, Lemaire M, Moenius T, Urwyler S, Whitebread S, Gasparini F, Auberson YP. 2007. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg Med Chem 15:903-914.
25. Ichise M, Toyama H, Innis RB, Carson RE. 2002. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22:1271-1281.
26. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
27. Kew JN, Kemp JA. 2005. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179:4-29.
28. Kuwabara K, Chamroonrat W, Mathews W, Waterhouse D, Brasic J, Guevara MR, Kumar A, Hamill T, Mozley PD, Wong DF. 2011. Evaluation of 11C-ABP688 and 18F-FPEB for imaging mGluR5 receptors in the human brain. J Nucl Med 52 (Suppl 1):390.
29. Lammertsma AA, Hume SP. 1996. Simplified reference tissue model for PET receptor studies. NeuroImage 4:153-158.
30. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20:423-451.
31. Liu CY, Jiang XX, Zhu YH, Wei DN. 2012. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: Role of brain-derived neurotrophic factor. Neuroscience 223C:219-224.
32. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. 2012. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49-56.
33. Miyake N, Skinbjerg M, Easwaramoorthy, B, Kumar D, Girgis RR, Xu X, Slifstein M, Abi-Dargham A. 2011. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol Psychiatry 69:822-824.
34. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
35. O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, Conn PJ, Williams DL Jr. 2003. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 64:731-740.
36. Pajevic S, Daube-Witherspoon ME, Bacharach SL, Carson RE. 1998. Noise characteristics of 3-D and 2-D PET images. IEEE Trans Med Imaging 17:9-23.
37. Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. 2007. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol 34:1009-1017.
38. Perroy J, Raynaud F, Homburger V, Rousset MC, Telley L, Bockaert J, Fagni L. 2008. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. J Biol Chem 283:6799-6805.
39. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E. 2012. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 100:752-774.
40. Sandiego CM, Weinzimmer D, Carson RE. 2013. Optimization of PET-MR registrations for nonhuman primates using mutual information measures: A Multi-Transform Method (MTM). NeuroImage 64:571-581.
41. Shen LH, Liao MH, Tseng YC. 2012. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol 2012:259349.
42. Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK. 2011. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76:1344-1352.
43. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R. 2003. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277.